E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« Conference & CLE Calendar | Main | ArQule v. Kappos: Enjoy Your Weekend, or What a Difference a Day (or Two or Three) of PTA Can Make »

September 30, 2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e2017c323f7933970b

Listed below are links to weblogs that reference U.S. Negotiators on TPP -- Don't Trade Away the Biopharmaceutical Research Sector:

Comments

This is all well-reasoned and indisputable among us in the choir. But let's get real. The current administration has gotten Obamacare passed and thus has no further need for the industry. If anything, the industry is an annoyance, coming up with expensive new therapies that patients will expect to be provided under various Government health programs, thereby aggravating the Federal fiscal disaster. In general, power and politics trumps jobs these days, so good luck on that support thing.

What specific proposals in the TPP negotiations prompted this piece? Reading between the lines, and recalling some earlier posts on this blog on the subject, it sounds like somebody or somebodies are advocating for (significantly) less than 12 years of data exclusivity for biopharmaceuticals (just as some carbon blobs who occupy space in Congress and consume our oxygen now advocate a change in Obamacare provisions to lessen the period of data exclusivity under domestic law).

The comments to this entry are closed.

October 2014

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31